Immunogenicity of a third dose with mRNA-vaccines in the ChAdOx1-S/BNT162b2 vaccination SARS-CoV-2 variants

被引：0

作者：

Garcia-Perez, Javier ^{[1
,2
]}

Borobia, Alberto M. ^{[3
,4
]}

Perez-Olmeda, Mayte ^{[2
,5
]}

Portoles, Antonio ^{[7
]}

Castano, Luis ^{[7
]}

Campins-Arti, Magdalena ^{[8
]}

Bertran, Maria Jesus ^{[9
]}

Bermejo, Mercedes ^{[1
,2
]}

Arribas, Jose Ramon ^{[2
,4
]}

Lopez, Andrea ^{[5
]}

Ascaso-del-Rio, Ana ^{[6
]}

Arana-Arri, Eunate ^{[7
]}

Camps, Inmaculada Fuentes ^{[10
]}

Vilella, Anna ^{[9
]}

Cascajero, Almudena ^{[1
]}

Garcia-Morales, Maria Teresa ^{[11
]}

de la Osa, Maria Castillo ^{[5
]}

Ingidua, Carla Perez ^{[6
]}

Lora, David ^{[11
,12
,13
]}

Jimenez-Santana, Paloma ^{[1
]}

Pino-Rosa, Silvia ^{[5
]}

de la Camara, Agustin Gomez ^{[12
,13
]}

de la Torre-tarazona, Erick ^{[1
]}

Calonge, Esther ^{[2
]}

Cruces, Raquel ^{[1
]}

Belda-Iniesta, Cristo bal ^{[14
]}

Alcami, Jose ^{[1
,2
]}

Frias, Jesus ^{[3
]}

Carcas, Antonio J. ^{[3
]}

Diez-Fuertes, Francisco ^{[1
,2
]}

机构：

[1] Inst Salud Carlos III ISCIII, Ctr Nacl Microbiologia, Unidad Inmunopatologi SIDA, Majadahonda 28222, Madrid, Spain

[2] Inst Salud Carlos III ISCIII, Ctr Invest Biomed Red Enfermedades Infecciosas CIB, Majadahonda 28222, Madrid, Spain

[3] Univ Autonoma Madrid, Hosp Univ La Paz, Fac Med, Dept Farmacologia & Terapeut,Serv Med Interna,IdiP, Madrid 28046, Spain

[4] Univ Autonoma Madrid, Hosp Univ La Paz, Fac Med, Serv Med Interna,Dept Med,IdiPAZ, Madrid 28046, Spain

[5] Inst Salud Carlos III ISCIII, Lab Serologia, Ctr Nacl Microbiologia, Majadahonda 28222, Madrid, Spain

[6] IdISSC, Serv Farmacologia Clin, Hosp Clin San Carlos, Madrid 28040, Spain

[7] Cruces Univ Hosp, Endo ERN, UPV EHU, CIBERDEM CIBERER,Biobizkaia, Baracaldo 48903, Vizcaya, Spain

[8] Univ Autonoma Barcelona, Hosp Univ Vall dHebron, Serv Med Prevent & Epidemiologia, Barcelona 08035, Spain

[9] Hosp Clin Barcelona, Serv Med Prevent & Epidemiologia, Barcelona 08036, Spain

[10] Hosp Univ Vall dHebron, Vall dHebron Inst Recerca, Serv Farmacologia Clin, Unidad Soporte Invest Clin, Barcelona 08035, Spain

[11] Spanish Clin Res Network SCReN ISCIII, Madrid 28029, Spain

[12] Inst Invest Sanitaria Hosp Univ 12 octubre, Madrid 28041, Spain

[13] Univ Complutense Madrid, Fac Estudios Estadist, Madrid 28040, Spain

[14] Directorate Inst Salud Carlos III, Madrid 28029, Spain

来源：

ISCIENCE | 2024年 / 27卷 / 09期

关键词：

D O I：

10.1016/j.isci.2024.110728

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

CombiVacS study has demonstrated a strong immune response of the heterologous ChAdOx1-S/BNT162b2 vaccine combination. The primary outcomes of the study were to assess the humoral immune response against SARS-CoV-2, 28 days after a third dose of a mRNA vaccine, in subjects that received a previous prime-boost scheme with ChAdOx1-S/BNT162b2. Secondary outcomes extended the study to 3 and 6 months. The third vaccine dose of mRNA-1273 in naive participants previously vaccinated with ChAdOx1-S/BNT162b2 regimen reached higher neutralizing antibodies titers against the variants of concern Delta and BA.1 lineage of Omicron compared with those receiving a third dose of BNT162b2 at day 28. These differences between BNT162b2 and mRNA-1273 arms were observed against the ancestral variant G614 at day 90. Suboptimal neutralizing response was observed against BQ.1.1, XBB.1.5/XBB.1.9, and JN.1 in a relevant proportion of individuals 180 days after the third dose, even after asymptomatic Omicron breakthrough infections. EudraCT (2021-001978-37); ClinicalTrials.gov (NCT04860739).

引用

页数：13

共 50 条

[21] Role of booster with BNT162b2 mRNA in SARS-CoV-2 vaccination in patients with rheumatoid arthritis
Benucci, Maurizio
Damiani, Arianna
Li Gobbi, Francesca
Lari, Barbara
Grossi, Valentina
Infantino, Maria
Manfredi, Mariangela
IMMUNOLOGIC RESEARCH, 2022, 70 (04) : 493 - 500
[22] Role of booster with BNT162b2 mRNA in SARS-CoV-2 vaccination in patients with rheumatoid arthritis
Maurizio Benucci
Arianna Damiani
Francesca Li Gobbi
Barbara Lari
Valentina Grossi
Maria Infantino
Mariangela Manfredi
Immunologic Research, 2022, 70 : 493 - 500
[23] Recurrent varicella following SARS-CoV-2 vaccination with BNT162b2
Nanova, Krassimira
Zlotogorski, Abraham
Ramot, Yuval
INTERNATIONAL JOURNAL OF DERMATOLOGY, 2021, 60 (09) : 1148 - 1149
[24] Third BNT162b2 mRNA SARS-CoV-2 Vaccine Dose Significantly Enhances Immunogenicity in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation
Henig, Israel
Isenberg, Jonathan
Yehudai-Ofir, Dana
Leiba, Ronit
Ringelstein-Harlev, Shimrit
Ram, Ron
Avni, Batia
Amit, Odelia
Grisariu, Sigal
Azoulay, Tehila
Slouzkey, Ilana
Zuckerman, Tsila
VACCINES, 2023, 11 (04)
[25] An Immunogenicity Report for the Comparison between Heterologous and Homologous Prime-Boost Schedules with ChAdOx1-S and BNT162b2 Vaccines
Vallee, Alexandre
Vasse, Marc
Mazaux, Laurence
Bonan, Brigitte
Amiel, Carline
Zia-Chahabi, Sara
Chan-Hew-Wai, Aurelie
Farfour, Eric
Camps, Eve
Touche, Pauline
Barret, Flavie
Parquin, Francois
Zucman, David
Fourn, Erwan
JOURNAL OF CLINICAL MEDICINE, 2021, 10 (17)
[26] Real-World Effectiveness and Immunogenicity of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Patients on Hemodialysis
Sibbel, Scott
McKeon, Katherine
Luo, Jiacong
Wendt, Karl
Walker, Adam G.
Kelley, Tara
Lazar, Rachael
Zywno, Meredith L.
Connaire, Jeffrey J.
Tentori, Francesca
Young, Amy
Brunelli, Steven M.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (01): : 49 - 57
[27] Immunogenicity and Safety of Half-Dose Heterologous mRNA-1273 Booster Vaccination for Adults Primed with the CoronaVac® and ChAdOx1-S Vaccines for SARS-CoV-2
Putri, Nina Dwi
Zhafira, Aqila Sakina
Wicaksana, Pratama
Sinto, Robert
Hanafi, Gryselda
Wiyono, Lowilius
Prayitno, Ari
Karyanti, Mulya Rahma
Naibaho, Murni Luciana
Febrina, Febrina
Sukandar, Hadyana
Setiawaty, Vivi
Mursinah, Mursinah
Putra, Ahmat Rediansya
Wibowo, Heri
Sundoro, Julitasari
Satari, Hindra Irawan
Oktavia, Dwi
Multihartina, Pretty
Harbuwono, Dante Saksono
Hadinegoro, Sri Rezeki
VACCINES, 2024, 12 (04)
[28] SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
Falsey, Ann R.
Frenck, Robert W., Jr.
Walsh, Edward E.
Kitchin, Nicholas
Absalon, Judith
Gurtman, Alejandra
Lockhart, Stephen
Bailey, Ruth
Swanson, Kena A.
Xu, Xia
Koury, Kenneth
Kalina, Warren
Cooper, David
Zou, Jing
Xie, Xuping
Xia, Hongjie
Tuereci, Ozlem
Lagkadinou, Eleni
Tompkins, Kristin R.
Shi, Pei-Yong
Jansen, Kathrin U.
Sahin, Ugur
Dormitzer, Philip R.
Gruber, William C.
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (17): : 1627 - 1629
[29] Robust immunogenicity of a third BNT162b2 vaccination against SARS-CoV-2 Omicron variant in a naive New Zealand cohort
Lavender, Brittany
Hooker, Caitlin
Frampton, Chris
Williams, Michael
Carson, Simon
Paterson, Aimee
Mcgregor, Reuben
Moreland, Nicole J.
Gell, Katie
Priddy, Frances H.
Wiig, Kjesten
Le Gros, Graham
Ussher, James E.
Brewerton, Maia
VACCINE, 2023, 41 (38) : 5535 - 5544
[30] A third dose SARS-CoV-2 BNT162b2 mRNA vaccine results in improved immune response in hemodialysis patients
Melin, Jan
Svensson, Maria K.
Albinsson, Bo
Winqvist, Ola
Pauksens, Karlis
UPSALA JOURNAL OF MEDICAL SCIENCES, 2022, 127 (01)

← 1 2 3 4 5 →